<DOC>
	<DOCNO>NCT00082576</DOCNO>
	<brief_summary>The primary objective confirm hypothesis azithromycin plus chloroquine non-inferior mefloquine treatment symptomatic , uncomplicated malaria due P. falciparum .</brief_summary>
	<brief_title>Azithromycin Plus Chloroquine Versus Mefloquine Treatment Uncomplicated Malaria Africa</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Written inform consent subject legally authorize representative Females male &gt; = 18 year age uncomplicated , symptomatic malaria indicate presence following : . ) Blood smear positive Plasmodium falciparum monoinfection , asexual parasitemia 1000 100,000 parasites/mL b . ) Fever history fever ( &gt; = 38.5 C/101.2 F rectal tympanic ; &gt; = 37.5 C/99.5 F axillary &gt; = 38 C/100.4 F oral ) within prior 24 hour Serum glucose &gt; = 60 mg/dL ( fingerstick peripheral blood collection ) Rapid diagnostic test ( Binax NOW ICT ) positive P. falciparum Subjects must willing treated inpatient set minimum three day Women childbearing potential must negative urine gonadotropin prior entry study must agree use adequate contraception entire study Severe complicate malaria include subject follow : . ) Impaired consciousness ( e.g . obtundation , unarousable coma ) , seizure ( seizure within 24 hour prior enrollment ) abnormal neurologic exam suggestive severe complicate malaria b . ) Hemoglobinuria c. ) Jaundice d. ) Respiratory distress ( respiratory rate &gt; = 30/min ) e. ) Persistent vomit f. ) Hematuria , report patient Presence nonfalciparum specie microscopy Pregnant breastfeeding woman History allergy hypersensitivity azithromycin macrolide , mefloquine relate compound ( e.g . quinine quinidine ) , chloroquine Known suspect folate deficiency Known history blood dyscrasia ( e.g. , megaloblastic anemia , agranulocytosis , aplastic anemia , thrombocytopenia , leukopenia , neutropenia , hemolytic anemia ) Known G6PD deficiency History epilepsy psoriasis History treatment antimalarial drug ( chloroquine , quinine , mefloquine , Malarone , SP , artemisinin compound ) antibacterial know antimalarial activity ( macrolides , doxycycline , clindamycin ) within 2 week prior enrollment study Known suspect cardiovascular , hepatic renal abnormality opinion Investigator would place subject increase risk participate study . The following finding specific exclusion : . ) Serum creatinine &gt; 2.0 x ULN b . ) ALT and/or AST &gt; 3 x ULN Active depression recent history depression , generalize anxiety disorder , psychosis , schizophrenia major psychiatric disorder Inability swallow oral medication tablet form Treatment investigational drug within 30 day prior enrollment study Alcohol and/or drug abuse Requirement use medication study might interfere evaluation study drug Specific systemic disease medical condition would interfere evaluation therapeutic response safety study drug Inability comprehend and/or unwillingness follow study protocol Prior participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>